Valeant Pharma (VRX) Reports Q3 EPS of $3.69, Beating Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Valeant Announces Third-Quarter 2017 Results
November 7, 2017 7:01 AM ESTLAVAL, Quebec, Nov. 7, 2017 /PRNewswire/ --
Strong Third-Quarter 2017 Financial Results Revenues of $2,219 million GAAP Net Income of $1,301 million Adjusted Net Income (non-GAAP) of $367 million GAAP Cash Flow From Operations of $490 million; Year-to-Date of $1,712 million Adjusted EBITDA (non-GAAP) of $951 million Delivered Strong Organic Growth1 (non-GAAP) in Bausch + Lomb/International Segment and Salix Business Exceeds $5 Billion Debt Reduction Commitment Early Updates 2017 Full-Year Revenue and Maintains Adjusted EBITDA (non-GAAP) Guidance Range Despite Asset DivestituresValeant... More
